1 September, 2023

PRECISION

2024-01-03T18:05:48+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: , |

Ongoing study Official Study Title Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial Brief Description The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The PRECISION is a proof-of-concept, phase II randomized clinical

27 December, 2022

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial

2023-02-16T12:27:12+03:00By |Categories: Publications, Therapeutics|Tags: , , , |

Karolina Akinosoglou, Antigone Kotsaki, Ioanna-Maria Gounaridi, Eirini Christaki, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Massimo Fantoni, Aggeliki Rapti, Ioannis Kalomenidis, Georgios Chrysos, Gloria Boni, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Asimina Safarika, Sofia Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios

19 December, 2022

Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia

2023-01-15T22:10:03+03:00By |Categories: Pathogenesis, Publications|Tags: , , |

Charilaos Samaras, Evdoxia Kyriazopoulou, Garyfallia Poulakou, Eran Reiner, Maria Kosmidou, Ioanna Karanika, Vasileios Petrakis, George Adamis, Nikolaos K. Gatselis, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, George Chrysos, Giulia Bertoli, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Sofia Koukidou, Glykeria Tzatzagou,

1 November, 2022

Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial

2023-02-16T12:33:52+03:00By |Categories: Multicenter studies in Greece, Publications|Tags: , , |

Konstantinos Leventogiannis, Evdoxia Kyriazopoulou, Nikolaos Antonakos, Antigone Kotsaki, Iraklis Tsangaris, Dimitra Markopoulou, Inge Grondman, Nikoleta Rovina, Vassiliki Theodorou, Eleni Antoniadou, Ioannis Koutsodimitropoulos, George Dalekos, Glykeria Vlachogianni, Karolina Akinosoglou, Vassileios Koulouras, Apostolos Komnos, Theano Kontopoulou, Athanassios Prekates, Antonia Koutsoukou, Jos WM van der Meer, George Dimopoulos, Miltiades Kyprianou, Mihai G Netea, Evangelos J. Giamarellos-Bourboulis

10 October, 2022

INSPIRE

2024-01-03T18:06:39+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: , |

Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard

1 October, 2021

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

2023-02-16T13:23:01+03:00By |Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: , , |

Evdoxia Kyriazopoulou, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Konstantinos Tsiakos, Archontoula Fragkou, Aggeliki Rapti, Christina Damoulari, Massimo Fantoni, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Maria Tsilika, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Panagiotis Koufargyris, Katerina Dimakou, Spyridon Savvanis, Glykeria

8 March, 2021

An open label trial of anakinra to prevent respiratory failure in COVID-19

2023-02-16T13:28:10+03:00By |Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: , , |

Evdoxia Kyriazopoulou, Periklis Panagopoulos, Symeon Metallidis, George N Dalekos, Garyphallia Poulakou, Nikolaos Gatselis, Eleni Karakike, Maria Saridaki, Georgia Loli, Aggelos Stefos, Danai Prasianaki, Sarah Georgiadou, Olga Tsachouridou, Vasileios Petrakis, Konstantinos Tsiakos, Maria Kosmidou, Vassiliki Lygoura, Maria Dareioti, Haralampos Milionis, Ilias C Papanikolaou, Karolina Akinosoglou, Dimitra-Melia Myrodia, Areti Gravvani, Aliki Stamou, Theologia Gkavogianni, Konstantina Katrini,

1 December, 2020

SAVE-MORE

2023-01-25T00:36:46+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early Management Of seveRE respiratory failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial Brief Description SAVE-MORE is a double-blind randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by

8 July, 2020

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

2023-02-16T14:27:57+03:00By |Categories: Pathogenesis, Publications|Tags: , |

George Dimopoulos, Quirijn de Mast, Nikolaos Markou, Maria Theodorakopoulou, Apostolos Komnos, Maria Mouktaroudi, Mihai G Netea, Themistoklis Spyridopoulos, Rebecca J Verheggen, Jacobien Hoogerwerf, Alexandra Lachana, Frank L van de Veerdonk, Evangelos J. Giamarellos-Bourboulis Cell Host & Microbe 2020 Jul 8;28(1):117-123.e1 DOI 10.1016/j.chom.2020.05.007Download pdf 🡇 Funding The study was funded in part by the

1 April, 2020

SAVE

2023-07-07T09:32:51+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker

Go to Top